Pediatr Blood Cancer. 2025 May 28:e31802. doi: 10.1002/pbc.31802. Online ahead of print.
ABSTRACT
Phase I trials of chimeric antigen receptor (CAR) T cells have shown remarkable promise in pediatric B-cell malignancies. Such outcomes have shifted expectations for other phase I CAR T-cell trials to have high response rates. The juxtaposition of high expectations, uncertain outcomes, and potential for life-threatening toxicities raises unique ethical considerations. To aid patients and providers considering early-phase CAR T-cell trials, we discuss: (i) considerations for enrollment of pediatric patients, (ii) understanding trial intent and expectations, (iii) weighing risks and benefits, (iv) considerations for informed consent discussions, (v) post CAR T-cell therapy expectations, (vi) barriers to access, and (vii) vulnerability in decision making.
PMID:40437658 | DOI:10.1002/pbc.31802
